Pharmacodynamic modeling

Hurwitz SJ, Schinazi RF (2002) Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors. Antiviral Res 56 115-127 Hurwitz SJ, Tennant BC, Korba BE, Gerin JL, Schinazi RF (1998) Pharmacodynamics of (—)-beta-2, 3 -dideoxy-3 -thiacytidine in chronically virus-infected woodchucks compared to its pharmacodynamics in humans, Antimicrob Agents Chemother 42 2804-2809 Hurwitz SJ, Otto MJ, Schinazi RF (2005) Comparative pharmacokinetics of Racivir, (+/-)-beta-2, 3 -dideoxy-5-fluoro-3 -thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans, Antivir Chem Chemother 16 117-127... [Pg.48]

Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, Glue P, Hajian G (2002) Ribavirin dosing in chronic hepatitis C application of population pharmacokinetic-pharmacodynamic models, Clin Pharmacol Ther 72 349-361... [Pg.235]

Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000 40 67-95. [Pg.525]

Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997 35 469-74. [Pg.525]

Schaddelee MP, Collins SD, DeJongh J, de Boer AG, Ijzerman AP, Danhof M. Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and antinociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain. Eur J Pharmacol 2005 May 9 514(2-3) 131-40. [Pg.553]

Duffal SB, Kimko HC (eds). Simulation for designing clinical trials a pharmacokinetic-pharmacodynamic modeling perspective (Drugs and the pharmaceutical sciences, Vol 127). New York Marcel Dekker, 2003... [Pg.553]

Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996 Dec 60(6) 619-35. [Pg.554]

Simulation for Designing Clinical Trials A Pharmacokinetic-Pharmacodynamic Modeling Perspective, edited by Hui C. Kimko and Stephen B. Duffull... [Pg.10]

Gobburu, J. V., Marroum, P. J., Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory dedsion-... [Pg.439]

Ratain MJ, Mick R, Janish L et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 1996 6 93-101. [Pg.307]

Andersen ME (1995) Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Lett 79 35-44... [Pg.136]

Part 2 Pharmacokinetic/Pharmacodynamic Modeling in New Drug Development... [Pg.345]

Pharmacokinetic/pharmacodynamic model using nonlinear, mixed-effects model in two compartment, best described time course of concentration strong correlation with creatinine clearance predicted concentration at the efi ect site and in reduction of heart rate during atrial fibrillation using population kinetic approach... [Pg.369]

Pharmacokinetic/pharmacodynamic modeling indicates that the AUC/MIC ratio is predictive of outcome for this antibacterial suggesting that telithromycin is suitable for short-duration therapy and a once-daily dosing regimen even against / -lactam and macrolide-resistant pathogens... [Pg.369]

Landoni, M.F. and Lees, P., Pharmacokinetic/pharmacodynamic modeling of non-steroidal anti-inflammatory drugs,/. Vet. Pharmacol. Ther., 20,118-120,1997. [Pg.374]

Mager, D.E. and Jusko, W.J., Pharmacodynamic modeling of time-dependent transduction systems, Clin. Pharmacol. Ther., 70, 210-216, 2001. [Pg.374]

Fuseau, E. and Sheiner, L.B., Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model, Clin. Pharmacol. Ther., 35, 733-741, 1984. [Pg.374]

Varlet-Marie, E., Gaudard, A., Audran, M., Gomeni, R., and Bressolle, F., Pharmacokinetic-pharmacodynamic modeling of recombinant human erythropoietin in athletes, Int. J. Sports Med., 24,2S2-2S7,2003. [Pg.374]

Lin, S. and Ghien, Y.W., Pharmacokinetic-pharmacodynamic modeling of insulin comparison of indirect pharmacodjmamic response with effect-compartment link models, J. Pharm. Pharmacol, 54, 791-800, 2002. [Pg.374]

Csajka, C., Buclin, T., Fattinger, K., Brunner, H.R., and Biollaz, Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers, Clin. Pharmacokinet., 41, 137-152, 2002. [Pg.376]

Miyazaki, M., Mukai, H., Iwanaga, K., Morimoto, K., and Kakemi, M., Pharmacokinetic-pharmacodynamic modeling of human insulin validity of pharmacological availability as a substitute for extent of bioavailability, /. Pharni. Pharmacol., 53, 1235-1246, 2001. [Pg.376]

Koopmans, R., Oosterhuis, B., Karemaker, J.M., Werner, J., and van Boxtel, C.J., Pharmacokinetic-pharmacodynamic modeling of oxprenolol in man using continuous non-invasive blood pressure monitoring, Eur.. Clin. Pharmacol., 34, 395-400,1988. [Pg.376]

Rohatagi, S. A future in pharmacokinetic and pharmacodynamic modeling. Curr Drug Discov 2004,... [Pg.423]

Rnally, pharmacokinetic and pharmacokinetic/pharmacodynamic modelling can be used for the purpose of prediction of the concentration-time profile of the drug and drug-carrier conjugate after repeated administration from single dose data, as well as for the prediction of the dose needed to maintain the concentration at the target site within a therapeutic window. [Pg.334]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...